COVID-19 trials registries data warehouse

http://en.irct.ir/trial/57938

Ahmed Farhan

drfarhan992@gmail.com

2021-08-13

Completed

RCT

Randomized

Parallel

Blind label

single-center

Treatment

Provide written informed consent Subjects age > 18 years at the time of signing the Informed Consent Form. Male or Female Must have a clinical diagnosis of COVID-19, with at least one clinical symptom (e.g., fever ≥38°C, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (RT-PCR) testing or equivalent. Individuals with severe COVID-19 symptoms according to Berlin Criteria Hospitalized patients and on Mechanical Ventilation Patients requiring FiO2 of 0.5 or more and a PEEP of 5 mmHg or more Ability to provide informed consent or an authorized representative can sign the informed consent

Pregnant females Patients with HIV infection. Patients with active tuberculosis or a history of treatment for pulmonary tuberculosis Patients with a CrCl of less than 30 ml/minute Patients with heart disease and an ejection fraction of 30% or less Patients with advanced liver disease Patients allergic to methylprednisolone

2

Pakistan Institute of Medical Sciences, Islamabad

18

60

Not reported

Severe disease at enrollment

6: Severe disease at enrollment

60

In-hospital mortality

Not reported

[{"arm_notes": "", "treatment_id": 798, "treatment_name": "Methylprednisolone", "treatment_type": "Corticosteroids", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]